First Quarter 2018 Investor Presentation
Investor Presentation
First three months of 2018
Slide 46
Novo Nordisk's modern and new generation insulins
maintain market share in the USA insulin market
USA fast-acting insulin
Segment volume
USA premix insulin
Segment volume
USA long-acting insulin
Segment volume Levemir® share
NovoLogⓇ share
NovoLog® Mix 70/30 share
TresibaⓇ share
tMU
tMU
CAGR volume¹: 3.3%
80
MI penetration: 83.9%
100%
80
CAGR volume¹: (6.1%)
MI penetration: 51.8%
tMU
CAGR volume¹: 4.2%
100%
80
MI penetration: 74.7%
100%
70
70
70
- 80%
80%
80%
60
60
60
50
- 60%
50
60%
50
60%
40
40
40
30
40%
30
40%
30
40%
20
20
20
20%
20%
20%
10
10
10
0
0%
0%
0
0%
0
Feb
2013
Feb
2018
Feb
Feb
Feb
Feb
2013
2018
2013
2018
1 CAGR for 5-year period; tMU: Thousand mega units
Note: US trend data reflect changes to IQVIA data collection coverage and methodology as of January 2012. Modern insulin (MI) penetration is of total segment, ie including human insulin
Source: IQVIA monthly MAT Feb, 2018 volume figures
changing
diabetes®
novo nordiskView entire presentation